 Home > Active Ingredient News > Antitumor Therapy > J Immunother Cancer: Ipilimumab + Nivolumab in the treatment of patients with metastatic renal cell carcinoma with brain metastases

J Immunother Cancer: Ipilimumab + Nivolumab in the treatment of patients with metastatic renal cell carcinoma with brain metastases

 Last Update: 2021-09-19
 Source: Internet
 Author: User

Tags

2 4 ester

3 cell batteries

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Previous studies have shown that Ipilimumab + Nivolumab (I+N) combination therapy greatly improves the prognosis of patients with intermediate- or high-risk untreated metastatic renal cell carcinoma (mRCC)

From October 2017 to December 2020, 19 patients with brain metastases received I+N therapy

The median follow-up time was 27.

OS and PFS

The median intracranial PFS was 14.

Intracranial and extracranial PFS

All responding patients were extracranial responses, which may be related to previous local CNS treatments

Efficacy evaluation

In summary, this retrospective study shows that Ipilimumab+Nivoluma has a certain clinical effect in the treatment of patients with metastatic renal cell carcinoma with brain metastases, and further exploration is needed

Original source:

Brown LC, Desai K, Wei W, et al.

Brown LC, Desai K, Wei W, et al.
Clinical outcomes in patients with metastatic renal cell carcinoma and brain metastasis treated with ipilimumab and nivolumab.
J Immunother Cancer.
2021 Sep;9(9):e003281.
doi: 10.
1136/jitc- 2021-003281.
PMID: 34518292.

Leave a message here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Gemcitabine Base 95058-81-4

CAS No.: 95058-81-4

$1-1.2/MT EXW

Amoxicillin Diketopiperazine

CAS No.: 2088961-37-7

Pharmacy Grade

$1.3-1.5/G FOB

Pentostatin powder High quality 99% Herbal extract White Powder cas 53910-25-1

CAS No.: 53910-25-1

Chemical Grade

$4-5/UNIT FOB

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

announcements today(81)

80 20 company(94)

united states logo(227)

single use technology(195)

healthy food name(42)

ups united states(221)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.